Drug Profile
PF 6294
Alternative Names: PF-6294Latest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Neuroprotectants
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Cognition-disorders in USA (SC, Injection)
- 16 Jul 2017 Pharmacodynamics data from preclinical trials in Cognition disorders presented at the Alzheimer's Association International Conference 2017 (AAIC-2017)
- 16 Jul 2017 Preclinical trials in Cognition disorders in USA (SC)